Basal-Bolus - Group A (N=12)~2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 continuous glucose monitoring (CGM) , followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with simplified bolus~6-month optional extension using Automated Mode~Basal - Group B (N=12)~2 weeks standard therapy - using basal injection only and Dexcom G6 continuous glucose monitoring (CGM) , followed by:~2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 continuous glucose monitoring (CGM) - with fixed basal rate, no bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR~If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus~6-month optional extension using Automated Mode
The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive.~Group A will complete a 2-week Standard Therapy Phase followed by 8 weeks of Omnipod 5 system use.~Group B will complete a 2-week Standard Therapy Phase followed by 10 weeks of Omnipod 5 system use.~Group A and Group B will have an optional 6-month extension of Omnipod 5 system use